Epidermal Growth Factor Receptor Inhibitor Gefitinib Added to Chemoradiotherapy in Locally Advanced Head and Neck Cancer

Journal of Clinical Oncology

Volumn 28, Issue 20, 2010, Pages 3336-3343

  Cohen, Ezra E W ^a   Haraf, Daniel J ^a   Kunnavakkam, Rangesh ^a   Stenson, Kerstin M ^a   Blair, Elizabeth A ^a   Brockstein, Bruce ^a   Lester, Eric P ^a   Salama, Joseph K ^a   Dekker, Allison ^a   Williams, Rosalyn ^a   Witt, Mary Ellyn ^a   Grushko, Tatyana A ^a   Dignam, James J ^a   Lingen, Mark W ^a   Olopade, Olufunmilayo I ^a   Vokes, Everett E ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; FLUOROURACIL; GEFITINIB; HYDROXYUREA; PACLITAXEL; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; QUINAZOLINE DERIVATIVE;

ADULT; ADVANCED CANCER; ALOPECIA; ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHEMORADIOTHERAPY; CONSTIPATION; CONTINUOUS INFUSION; CORRELATION ANALYSIS; DIARRHEA; DISEASE SEVERITY; DRUG ERUPTION; DRUG FEVER; FATIGUE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GENE DOSAGE; HAND FOOT SYNDROME; HEAD AND NECK CANCER; HUMAN; HYPOPHARYNX CANCER; INFECTION; LARYNX CANCER; LOCALLY ADVANCED HEAD AND NECK CANCER; MAJOR CLINICAL STUDY; MALE; MOUTH CANCER; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NASOPHARYNX CANCER; NAUSEA; NEUROTOXICITY; NEUTROPENIA; OROPHARYNX CANCER; OUTCOME ASSESSMENT; PAIN; PRIMARY TUMOR; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIATION DERMATITIS; THROMBOCYTOPENIA; VOMITING; AGED; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; DRUG ANTAGONISM; HEAD AND NECK TUMOR; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; PHASE 2 CLINICAL TRIAL;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 77954737028     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.27.0397     Document Type: Article

References (30)

1. Parkin DM, Pisani P, Ferlay J: Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer 80:827-841, 1999
2. Seiwert TY, Cohen EE: State-of-the-art management of locally advanced head and neck cancer. Br J Cancer 92:1341-1348, 2005 (Pubitemid 40704997)
3. Pignon JP, le Maitre A, Maillard E, et al: Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomised trials and 17,346 patients. Radiother Oncol 92:4-14, 2009
4. Posner MR, Hershock DM, Blajman CR, et al: Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 357:1705-1715, 2007 (Pubitemid 350005152)
5. Vermorken JB, Remenar E, van Herpen C, et al: Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 357:1695-1704, 2007 (Pubitemid 350005151)
6. Pointreau Y, Garaud P, Chapet S, et al: Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation. J Natl Cancer Inst 101:498-506, 2009
7. Rubin Grandis J, Melhem MF, Gooding WE, et al: Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 90:824-832, 1998 (Pubitemid 28280548)
8. Bonner JA, Harari PM, Giralt J, et al: Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354:567-578, 2006 (Pubitemid 43209104)
9. Chen C, Kane M, Song J, et al: Phase I trial of gefitinib in combination with radiation or chemoradiation for patients with locally advanced squamous cell head and neck cancer. J Clin Oncol 25:4880-4886, 2007 (Pubitemid 350220417)
10. Shin DM, Donato NJ, Perez-Soler R, et al: Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer. Clin Cancer Res 7:1204-1213, 2001 (Pubitemid 32708671)
11. Pfister DG, Su YB, Kraus DH, et al: Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: A pilot phase II study of a new combined-modality paradigm. J Clin Oncol 24:1072-1078, 2006 (Pubitemid 46638804)
12. Harari PM, Huang S: Radiation combined with EGFR signal inhibitors: Head and neck cancer focus. Semin Radiat Oncol 16:38-44, 2006 (Pubitemid 41832314)
13. Cohen EE, Rosen F, Stadler WM, et al: Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 21:1980-1987, 2003
14. Salama JK, Stenson KM, Kistner EO, et al: Induction chemotherapy and concurrent chemoradiotherapy for locoregionally advanced head and neck cancer: A multi-institutional phase II trial investigating three radiotherapy dose levels. Ann Oncol 19:1787-1794, 2008
15. Cohen EE, Davis DW, Karrison TG, et al: Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: A phase I/II study. Lancet Oncol 10:247-257, 2009
16. Chung CH, Ely K, McGavran L, et al: Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. J Clin Oncol 24:4170-4176, 2006 (Pubitemid 46622295)
17. Ang KK, Berkey BA, Tu X, et al: Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 62:7350-7356, 2002 (Pubitemid 36025259)
18. Temam S, Kawaguchi H, El-Naggar AK, et al: Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer. J Clin Oncol 25:2164-2170, 2007 (Pubitemid 46954638)
19. Caponigro F, Romano C, Milano A, et al: A phase I/II trial of gefitinib and radiotherapy in patients with locally advanced inoperable squamous cell carcinoma of the head and neck. Anticancer Drugs 19:739-744, 2008
20. Harrington KJ, El-Hariry IA, Holford CS, et al: Phase I study of lapatinib in combination with chemoradiation in patients with locally advanced squamous cell carcinoma of the head and neck. J Clin Oncol 27:1100-1107, 2009
21. Argiris AE, Gibson MK, Heron DE, et al: Phase II trial of neoadjuvant docetaxel (T), cisplatin (P), and cetuximab (E) followed by concurrent radiation (X), P, and E in locally advanced head and neck cancer. J Clin Oncol 26:316s, 2008 (abstr 6002)
22. Langer CJ, Lee JW, Patel UA, et al: Preliminary analysis of ECOG 3303: Concurrent radiation (RT), cisplatin (DDP) and cetuximab (C) in unresectable, locally advanced (LA) squamous cell carcinoma of the head and neck. J Clin Oncol 26:317s, 2008 (abstr 6006)
23. Wirth LJ, Allen AM, Posner MR, et al: Phase I dose-finding study of paclitaxel with panitumumab, carboplatin and intensity-modulated radiotherapy in patients with locally advanced squamous cell cancer of the head and neck. Ann Oncol 21:342-347, 2010
24. Cohen EE, Kane MA, List MA, et al: Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Clin Cancer Res 11:8418-8424, 2005 (Pubitemid 41746956)
25. Stewart JS, Cohen EE, Licitra L, et al: Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected]. J Clin Oncol 27:1864-1871, 2009
26. Trotti A, Bellm LA, Epstein JB, et al: Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: A systematic literature review. Radiother Oncol 66:253-262, 2003 (Pubitemid 36556043)
27. Kelly K, Chansky K, Gaspar LE, et al: Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J Clin Oncol 26:2450-2456, 2008
28. Licitra L, Rolland F, Bokemeyer C, et al: Biomarker potential of EGFR gene copy number by FISH in the phase III EXTREME study: Platinum-based CT plus cetuximab in first-line R/M SCCHN. J Clin Oncol 27:302s, 2009 (abstr 6005)
29. Burtness B, Goldwasser MA, Flood W, et al: Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: An Eastern Cooperative Oncology Group study. J Clin Oncol 23:8646-8654, 2005 (Pubitemid 46211507)
30. Hennessey PT, Westra WH, Califano JA: Human papillomavirus and head and neck squamous cell carcinoma: Recent evidence and clinical implications. J Dent Res 88:300-306, 2009